摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯甲基噁唑并[4,5-b]吡啶 | 110704-34-2

中文名称
2-氯甲基噁唑并[4,5-b]吡啶
中文别名
2-氯甲基唑并[4,5-B]吡啶;1-环丁基哌啶-4-胺;2-氯甲基恶唑并[4,5-B]吡啶;2-(氯甲基)-1,3-恶唑并[4,5-b]吡啶
英文名称
2-(chloromethyl)[1,3]oxazolo[4,5-b]pyridine
英文别名
2-(chloromethyl)oxazole<4,5-b>pyridine;2-chloromethyloxazolo<4,5-b>pyridine;2-chloromethyl-oxazolo[4,5-b]pyridine;2-chloromethyloxazolo[4,5-b]pyridine;2-(Chloromethyl)oxazolo[4,5-b]pyridine;2-(chloromethyl)-[1,3]oxazolo[4,5-b]pyridine
2-氯甲基噁唑并[4,5-b]吡啶化学式
CAS
110704-34-2
化学式
C7H5ClN2O
mdl
MFCD06659615
分子量
168.583
InChiKey
MUBURDYXGKXMFA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    115-118 °C
  • 沸点:
    252.5±20.0 °C(Predicted)
  • 密度:
    1.399±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT

SDS

SDS:33cdc4aeedeeb84f575a03f2cc165df3
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-(Chloromethyl)-1,3-oxazolo[4,5-b]pyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Chloromethyl)-1,3-oxazolo[4,5-b]pyridine
CAS number: 110704-34-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN2O
Molecular weight: 168.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
    申请人:Cowart D. Marlon
    公开号:US20060172995A1
    公开(公告)日:2006-08-03
    The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B, are as described in the specification.
    本发明涉及使用公式(I)化合物的用途,用于治疗性功能障碍,以及包含用于治疗性功能障碍的公式(I)化合物的组合物,其中A、L、D和B如说明书中所述。
  • Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogs of 3-aminopyridin-2(1H)-one
    作者:Walfred S. Saari、John S. Wai、Thorsten E. Fisher、Craig M. Thomas、Jacob M. Hoffman、Clarence S. Rooney、Anthony M. Smith、James H. Jones、Dona L. Bamberger
    DOI:10.1021/jm00099a007
    日期:1992.10
    A series of nonnucleoside 3-aminopyridin-2(1H)-one derivatives was synthesized and evaluated for HIV-1 RT inhibitory properties. Several analogs proved to be potent and highly selective antagonists with in vitro IC50 values as low as 19 nM in the enzyme assay using rC.dG as template-primer. Two compounds from this series, 3-[[(4,7-dimethylbenzoxazol-2-yl)methyl]-amino]-5-ethyl-6-methy lpyridin-2(1H)-one
    合成了一系列非核苷3-氨基吡啶-2(1H)-一衍生物,并评估了其对HIV-1 RT的抑制作用。在使用rC.dG作为模板引物的酶分析中,几种类似物被证明是有效的高选择性拮抗剂,体外IC50值低至19 nM。该系列中的两种化合物,3-[[[(4,7-二甲基苯并恶唑-2-基)甲基]-氨基] -5-乙基-6-甲基吡啶2-2(1H)-一个(34,L-697,639)和相应的4,7-二氯类似物(37,L-697,661)在浓度为25-50 nM的MT4细胞培养物中可抑制HIV-1 IIIb感染的传播达95%,并被选作临床试验的抗病毒药。
  • [EN] FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION<br/>[FR] COMPOSES AROMATIQUES BICYCLIQUES CONDENSES UTILES DANS LE TRAITEMENT DE DYSFONCTIONNEMENT SEXUEL
    申请人:ABBOTT LAB
    公开号:WO2003101994A1
    公开(公告)日:2003-12-11
    The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    本发明涉及使用化合物(I)的治疗性功能障碍,并涉及含有化合物(I)的组合物用于治疗性功能障碍。
  • Process for preparing chloromethyl thiazoles or oxazoles, and
    申请人:Pfizer Inc.
    公开号:US04723010A1
    公开(公告)日:1988-02-02
    Chloromethyl group substituted heterocyclic compounds of the formulae ##STR1## wherein X is O or S; Y together with the two carbons to which Y is attached forms phenyl, pyridyl or pyrimidyl, each of which may be substituted by R; R is one of iodo or trifluoromethylthio or one or two of fluoro, chloro, bromo, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl or trifluoromethyl; and R.sup.1 is hydrogen or R, are prepared by reacting a bifunctional compound of the formulae ##STR2## with a 2-chloro-1,1,1-tri(C.sub.1 -C.sub.6)alkoxyethane. Most of the compounds of formulae I and II are novel. These compounds are intermediates of use in the preparation of compounds having pharmaceutical activity. The 2-chloro-1,1,1-tri(C.sub.1 -C.sub.6)alkoxyethanes are prepared from the corresponding tri(C.sub.1 -C.sub.6)alkoxyethanes by chlorination with N-chlorosuccinimide or with chlorine in pyridine and a chlorohydrocarbon cosolvent.
    式为##STR1##的氯甲基取代的杂环化合物,其中X为O或S; Y与Y附着的两个碳形成苯基、吡啶基或嘧啶基,每个基团都可以被R取代; R为碘或三氟甲硫基或一到两个氟、氯、溴、(C.sub.1-C.sub.4)烷基、(C.sub.1-C.sub.4)烷氧基、(C.sub.1-C.sub.4)烷硫基、(C.sub.1-C.sub.4)烷基亚砜基、(C.sub.1-C.sub.4)烷基磺酰基或三氟甲基之一; R.sup.1为氢或R,通过将式为##STR2##的双官能团化合物与2-氯-1,1,1-三(C.sub.1-C.sub.6)烷氧基乙烷反应制备而成。大多数I和II式化合物是新的。这些化合物是制备具有药物活性的化合物的中间体。2-氯-1,1,1-三(C.sub.1-C.sub.6)烷氧基乙烷是通过使用N-氯代琥珀酰亚胺或在吡啶和氯代烃共溶剂中使用氯气进行氯化制备的。
  • Certain chlorination process for preparing 2-chloro-1,1,1-(C.sub.1 -C.sub.6
    申请人:Pfizer Inc.
    公开号:US04748280A1
    公开(公告)日:1988-05-31
    The 2-chloro-1,1,1-tri(C.sub.1 -C.sub.6)alkoxyethanes are prepared from the corresponding tri(C.sub.1 -C.sub.6)alkoxyethanes by chlorination with N-chlorosuccinimide or with chlorine in pyridine and a chlorohydrocarbon cosolvent.
    2-氯-1,1,1-三(C.sub.1-C.sub.6)烷氧乙烷是通过使用N-氯代琥珀酰亚胺或在吡啶和氯代烃共溶剂中使用氯气进行氯化反应而制备出对应的三(C.sub.1-C.sub.6)烷氧乙烷得到的。
查看更多

同类化合物

甲基吡噁磷 甲基吡啶磷-d6 恶唑并[5,4-B]吡啶-2-胺二盐酸盐 恶唑并[5,4-B]吡啶-2-胺 恶唑并[5,4-B]吡啶-2(1H)-硫酮 恶唑并[4,5-B]吡啶-2(3H)硫酮 噁唑并[5,4-c]吡啶-2-胺 噁唑并[5,4-c]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶 噁唑并[4,5-c]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-羧酸乙酯 噁唑并[4,5-b]吡啶-2(3H)-酮,6-溴-3-(苯基甲基)- 噁唑并[4,5-b]吡啶-2(3H)-酮,6-乙酰基-3-[2-(2-吡啶基)乙基]- 噁唑并[4,5-b]吡啶-2(3H)-酮,3-(2-羰基丙基)- 噁唑并[4,5-b]吡啶,2-(1-甲基乙基)-(9CI) 噁唑并[4,5-b]吡啶 噁唑并[4,5-C]吡啶-2(3H)-硫酮 噁唑并[4,5-C]吡啶 [1,3]恶唑并[4,5-c]吡啶-6-羧酸 7-溴恶唑并[4,5-C]吡啶 7-溴-2-甲基-F唑并[4,5-C]吡啶 7-溴-2-乙基恶唑并[4,5-C]吡啶 6-溴恶唑并[5,4-B]吡啶-2-胺 6-溴恶唑并[5,4-B]吡啶 6-溴噁唑并[4,5-b]吡啶 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 6-溴-2-甲基噁唑并[5,4-b]吡啶 6-溴-2-甲基噁唑并[4,5-B]吡啶 6-溴-2-(三氟甲基)噁唑并[5,4-B]吡啶 6-溴-2-(三氟甲基)噁唑并[4,5-b]吡啶 6-氯恶唑并[4,5-b]吡啶-2(3H)-酮 5-甲基噁唑并[4,5-b]吡啶-2(3h)-酮 5-甲基-3H-恶唑并[4,5-B]吡啶-2-硫酮 5-溴-3H-恶唑并[4,5-b]吡啶-2-酮 3-[2-(4-氯苯基)乙基]-2-苯基亚氨基-1,3-噻唑烷-4-酮 3-(2-溴乙基)恶唑并[4,5-b]吡啶-2(3H)-酮 3-(2-吗啉-4-基乙基)[1,3]噁唑并[4,5-b]吡啶-2(3H)-酮 2-甲硫基唑并[4,5-B]吡啶 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 2-甲基噁唑并[5,4-c]吡啶 2-甲基噁唑并[5,4-b]吡啶 2-甲基吡啶并噁唑 2-甲基[1,3]噁唑并[4,5-b]吡啶 2-氯甲基噁唑并[4,5-b]吡啶 2-氯恶唑并[5,4-b]吡啶 2-氯恶唑并[5,4-C]吡啶盐酸盐 2-氯恶唑并[5,4-C]吡啶 2-氯噁唑并[4,5-B]吡啶